Phase-contrast study of the efficacy of Lampit (BAY 2502, Nifurtimox) on experimental infection with Trypanosoma rhodesiense.
Lampit (BAY 2502, Nifurtimox) was tested in experimental Wistar strain white rats with acute infection induced by Trypanosoma rhodesiense strain (180 TS1A1), which normally contains cytoplasmic granules of both Type (I) & (II). Lampit injected subcutaneously in low doses of 25, 50, 100, and 250 mg/kg b-w as one-time application, gave no effect. When repeated higher doses (500 mg/kg b-w) was given a reasonable effect was achieved and formation of additional granules in T. rhodesiense was noticed. In experimental animals, some what higher initial doses appear to be particularly advantageous.
Soliman
M A
MA
Department of Parasitology, Faculty of Medicine, Al-Azhar University, Egypt.
D000818:Animals; D008858:Microscopy, Phase-Contrast; D009547:Nifurtimox / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D014346:Trypanosoma brucei brucei / Q000187:drug effects*; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D009547:Nifurtimox